How did Avanos Medical's revenue and expenses trend in Q4 2024?

Avanos Medical's revenue and expenses in Q4 2024 are as follows: 1. **Revenue by Business Segment**: The company's revenue was $396.4 million, with the business segment being the primary categorization. 2. **Net Income**: The net income for Q4 2024 was -$397.3 million, indicating a significant loss for the period. 3. **Operating Expenses**: The operating expenses were $5.7 million, which is a relatively small portion of the total revenue. 4. **Research and Development Expenses**: The R&D expenses were not provided separately, but they are likely to be included in the operating expenses or other categories. 5. **Selling, General, and Administrative Expenses**: The SG&A expenses were $79.7 million, which is a substantial amount compared to the net income. |code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code| |---|---|---|---|---|---|---| |AVNS|AVNS.N|Avanos Medical|20240101-2024|Pain Management and Recovery|2.914E8|169| |AVNS|AVNS.N|Avanos Medical|20240101-2024|Pain Management and Recovery|2.176E8|169| |AVNS|AVNS.N|Avanos Medical|20240101-2024|Pain Management and Recovery|1.454E8|169| |AVNS|AVNS.N|Avanos Medical|20240101-2024|Pain Management and Recovery|7.14E7|169| |AVNS|AVNS.N|Avanos Medical|20240101-2024|Chronic Care|9.47E7|169| |AVNS|AVNS.N|Avanos Medical|20240101-2024|Pain Management and Recovery|7.14E7|169| |code|Ticker|Name|Date|Net Income YoY|Net Income|market_code| |---|---|---|---|---|---|---| |AVNS|AVNS.N|Avanos Medical|2024 Q1|-80|-900000|169| |AVNS|AVNS.N|Avanos Medical|2024 Q2|102.6431718061674|1800000|169| |AVNS|AVNS.N|Avanos Medical|2024 Q3|216.21621621621622|4300000|169| |AVNS|AVNS.N|Avanos Medical|2024 Q4|-3883.8095238095234|-3.973E8|169| |code|Ticker|Name|Date|Selling, General, and Administrative Expenses|R&D Expenses|Selling, General, and Administrative Expenses YoY|Operating Expenses YoY|Operating Expenses|R&D Expenses YoY|market_code| |---|---|---|---|---|---|---|---|---|---|---| |AVNS|AVNS.N|Avanos Medical|20240331|8.36E7|7000000|-5.8558558558558556|||-6.666666666666667|169| |AVNS|AVNS.N|Avanos Medical|20240630|8.09E7|6300000|-13.010752688172042|||-7.352941176470589|169| |AVNS|AVNS.N|Avanos Medical|20240930|7.43E7|7200000|-5.5908513341804325|||18.0327868852459|169| |AVNS|AVNS.N|Avanos Medical|20241231|7.97E7|5700000|6.97986577181208|||-16.176470588235293|169| Overall, Avanos Medical experienced a total revenue of $396.4 million in Q4 2024, with a notable net loss of $397.3 million. The SG&A expenses were significant, totaling $79.7 million, which could be a concern for the company's financial health. The R&D expenses are not separately disclosed, but they are likely to be a part of the operating expenses.